Clinical Trial: Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/tyrosine Kinase Inhibitors with or Without TACE for Advanced HCC with Vascular Invasions

U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT06881446) titled 'Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/tyrosine Kinase Inhibitors with or Without TACE for Advanced HCC with Vascular Invasions' on March 12.

Brief Summary: Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma with vascular invasions

Study Start Date: June 01, 2018

Study Type: OBSERVATIONAL

Condition: Hepatocellular Carcinoma (HCC)

Recruitment Status: RECRUITING

Sponsor: Zhongda Hospital

Information provided by (Respons...